Wakefulness-Promoting Agents
"Wakefulness-Promoting Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific category of drugs that prevent sleepiness by specifically targeting sleep-mechanisms in the brain. They are used to treat DISORDERS OF EXCESSIVE SOMNOLENCE such as NARCOLEPSY. Note that this drug category does not include broadly-acting central nervous system stimulants such as AMPHETAMINES.
| Descriptor ID |
D064690
|
| MeSH Number(s) |
D27.505.954.427.220.612
|
| Concept/Terms |
Wakefulness-Promoting Agents- Wakefulness-Promoting Agents
- Agents, Wakefulness-Promoting
- Wakefulness Promoting Agents
- Wake-Promoting Substances
- Substances, Wake-Promoting
- Wake Promoting Substances
- Wake-Promoting Drugs
- Drugs, Wake-Promoting
- Wake Promoting Drugs
- Wake-Promoting Agents
- Agents, Wake-Promoting
- Wake Promoting Agents
- Eugeroic Drugs
- Drugs, Eugeroic
|
Below are MeSH descriptors whose meaning is more general than "Wakefulness-Promoting Agents".
Below are MeSH descriptors whose meaning is more specific than "Wakefulness-Promoting Agents".
This graph shows the total number of publications written about "Wakefulness-Promoting Agents" by people in this website by year, and whether "Wakefulness-Promoting Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Wakefulness-Promoting Agents" by people in Profiles.
-
Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature. J Neurol Sci. 2018 10 15; 393:1-3.
-
Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes. Sleep Med. 2017 Jul; 35:12-16.
-
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016 08; 24:57-62.
-
Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev. 2016 Apr 13; 4:CD011376.
-
Modafinil combined with cognitive training is associated with improved learning in healthy volunteers--a randomised controlled trial. Eur Neuropsychopharmacol. 2014 Apr; 24(4):529-39.
-
Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict Biol. 2014 Jan; 19(1):49-60.